Results 101 to 110 of about 3,406,203 (262)
Molecular Oncology, EarlyView.Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla +9 more
wiley +1 more source
More pessimism than greediness: a characterization of monotone risk aversion in the Rank-Dependent Expected Utility model [PDF]
This paper studies monotone risk aversion, the aversion to monotone, meanpreserving increase in risk (Quiggin [21]), in the Rank Dependent Expected Utility (RDEU) model.
Michèle Cohen +2 more
core
, 2005 application/pdf; "February 9, 2005."; Testimony before the Kansas Legislature, House Utilities Committee, presented by David Springe, Consumer Counsel, Citizens' Utility Ratepayer Board.Testimony in opposition to House Bill 2084.
Springe, David.
core +1 more source
Nonhuman Primates Satisfy Utility Maximization in Compliance with the Continuity Axiom of Expected Utility Theory. [PDF]
J Neurosci, 2021 Ferrari-Toniolo S +4 more
europepmc +1 more source
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Preferences for Shifts in Probabilities and Expected Utility Theory [PDF]
We translate preferences over lotteries into preferences over “shifts in probabilities”. We define the independence axiom for such preferences. Next we construct and expected utility function to represent the preferences and present the corresponding ...
David Cantalá
core
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining
Molecular Oncology, EarlyView.IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis +3 more
wiley +1 more source
Great Expectations. Part I: On the Customizability of Generalized Expected Utility [PDF]
Many different rules for decision making have been introduced in the literature. We present a single framework in which to study and compare these rules.
Francis C. Chu, Joseph Y. Halpern
core
Molecular Oncology, EarlyView.Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens +6 more
wiley +1 more source